

# When customers know more about own genetic profile: a threat or opportunity?

### David Lu, Chief Medical Officer, Asia, Swiss Re

# Chengolu IFoA Asia Conference 2019 9-10 May, Chengdu, China

## What is genetic testing?


NIH U.S. National Library of Medicine


- Genetic testing is a type of medical test that identifies changes in chromosomes, genes, or proteins.
- The results of a genetic test can confirm or rule out a suspected genetic condition or help determine a person's chance of developing or passing on a genetic disorder.




### **Mono-genetic disorders**

 Mono-genetic disorders are caused by DNA changes in one particular gene, and often have predictable inheritance patterns.











## Multifactorial / Polygenic (complex) genetic disorders

- Polygenic and environmental factors contribute significantly to chronic, non-communicable diseases such as coronary heart disease, cancer, diabetes mellitus, asthma, gout, schizophrenia and osteoporosis.
- A genetic component to the disease contributes a certain percent (for schizophrenia it is estimated to be approximately 70%), but no single gene is responsible.


Selected examples of available multi-gene NGS panels # Genes							
Cancer Hereditary cancers (breast, colon, ovarian) <sup>1</sup> 10-50							
Cardiac diseases	Cardiomyopathies Arrhythmias (ex Long QT syndrome) Aortopathies (Marfan's syndrome)	50-70 10-30 10					
Neurologic disorders	Parkinsons disease Alzheimers disease Epilepsy Muscular dystrophy	30 30 53-120 12-45					

Rehm H, Nature Genetics 2013 14:295-300





# Moving from genetic testing to whole genome sequencing




Source: http://www.humanlongevity.com/






## Full genome sequencing becomes affordable



## Genetic testing in clinical practice has increased more than 20% annually in recent years

Trend in UK clinical genetic testing activity



There are positive correlations between better understanding of human genetics and availability and uptake of genetic testing in clinical practice

Swiss Re



## 23and Me & Co: A booming Direct-To-Consumer market



### Carrier Status\*\*

If you are starting a family, find out if you are a carrier for certain inherited conditions.

### Genetic Health Risks\*\*

Learn how your genetics can influence your risk for certain diseases.

### Ancestry

Discover where your DNA is from out of 31 populations worldwide - and more.

### Traits



Learn how your DNA influences your facial features, taste, smell and other traits.

### Wellness

Learn how your genes play a role in your wellbeing and lifestyle choices.

### 40+ reports including:

- Polycystic Kidney Disease
- Cystic Fibrosis
- Hereditary Hearing Loss

### **5 reports including:**

- BRCA1/2 (selected variants) NEW!
- Late-Onset Alzheimer's
- Disease Parkinson's Disease

### **5 reports including:**

- Ancestry Composition
- Your DNA Family
- DNA Relative Finder tool


### **5 reports including:**

- Hair loss
- Sweet vs. salty
- Unibrow, freckles...


### 21 reports including:

- Deep sleep
- Lactose intolerance
- Genetic weight

### 23andMe customer development




## There are many types of genetic testing





## **BRCA** mutations increase the risk of multiple cancers

### BRCA1/2 LIFETIME CANCER RISKS (%)



## Liquid biopsy





### 🔟 Swiss Re

A blood test that can detect cancer? Liquid biopsy: A potential diagnostic to watch close

"Liquid biopsy" is a new molecular technology being explored for its use in helping to treat – and detect – cancer. While the new test could ultimately benefit cancer patients and improve survival outcomes, it also creates new risks and exposures for life and health insurers, particularly for critical illness and cancer products.

A liquid biopsy is not really a "biopsy" but rather a molecular cancer test that uses body fluids.

Traditional tumour biopsies remain the standard for diagnosis and should be used for underwriting and claims assessment.

#### Key facts

 Liquid blocsy is a minimally investive technicue that can identify genetic material from tumour cells shed into the blood from a primary tumour or metastatic site.

 Liquid biopsy is being tested for its use to monitor a patient's response to treatment, to identify actionable genetic markers for targeted therapy, to support disease prognosis and to detect disease recurrence.

 Only one liquid biopsy test has obtained US FDA approval for use as a companion diagnost c in olinical practice to identify lung cancer patients eligible for a targeted therapy

 For the foreseeable future, histopathology will remain the standard for cancer diagnosis and staging.

 Far more research and clinical trials are needed to establish liquid biopsy as an acceptable screening tool and as a substitute or adjunct for conventional cancer diagnosis.

 A "negative" liquid biopsyltest does not rule out the presence of cancer

 A "positive" liquid biopsylest does not need locay's clinical standard for cancer diagnosis, and therefore any critical illness claims should continue to require histopathological proof.



Risk considerations for insurers

Liquid biology is less investre than extraoring tissue, easier to obtain and holds the obtainal to transform of incal practice. If it should be come an adopted and routine alternative to held orignose, certine and tract anover inverse, it raises the tables for insurers and requires careful consideration to manage issues like and-selection, over-diagnosis and to ensure our products remain sustainable and able to cover the people who need them the most.





## **Circulating tumor-derived DNA testing for nasopharyngeal carcinoma (NPC) screening**

#### ORIGINAL ARTICLE

Analysis of Plasma Epstein–Barr Virus DNA to Screen for Nasopharyngeal Cancer

K.C. Allen Chan, F.R.C.P.A., John K.S. Woo, F.R.C.S., Ann King, F.R.C.R., Benny C.Y. Zee, Ph.D., W.K. Jacky Lam, F.R.C.S., Stephen L. Chan, F.R.C.P., Sam W.I. Chu, B.S.c., Constance Mak, B.S.N., Irene O.L. Tse, B.N., Samantha Y.M. Leung, B.N., Gloria Chan, R.N., Edwin P. Hui, F.R.C.P., et al.

Table 2. Sensitivity and Specificity of the Two-Stage Screening Protocol for the Detection of Nasopharyngeal Carcinoma.*							
Finding	Screen-Positive (N=308)†	Screen-Negative (N=19,865)					
Confirmed nasopharyngeal carcinoma by the screening protocol or nasopharyngeal carcinoma reported to have developed within 1 yr — no.	34	1					
No nasopharyngeal carcinoma within 1 yr after screening — no.	274	19,864					
Sensitivity — % (95% CI)	97.1 (95.5–98.7)						
Specificity — % (95% CI)	98.6 (98.6–98.7)						
Positive predictive value — % (95% CI)	11.0 (10.7–11.3)						
Negative predictive value — % (95% CI)	99.995 (99.99–100.00)						
Proportion of stage I/II disease in the 34 cases of nasopharyngeal carcinoma identified by screening — % (95% CI)	70.6 (69.6–72.5)						

\* Screen-positive is defined as persistently positive for plasma EBV DNA at baseline and at follow-up. Screen-negative is defined as negative for plasma EBV DNA either at baseline or at follow-up.

† The participant who had declined further investigation but in whom advanced nasopharyngeal carcinoma developed 32 months after screening is not included in this number.

https://www.nejm.org/doi/full/10.1056/nejmoa1701717

## Sequencing-based counting and size profiling of plasma Epstein–Barr virus DNA enhance population screening of nasopharyngeal carcinoma

W. K. Jacky Lam<sup>a,b,c,d,1</sup>, Peiyong Jiang<sup>a,b,c,1</sup>, K. C. Allen Chan<sup>a,b,c,1</sup>, Suk H. Cheng<sup>a,b</sup>, Haiqiang Zhang<sup>a,b</sup>, Wenlei Peng<sup>a,b</sup>, O. Y. Olivia Tse<sup>a,b</sup>, Yu K. Tong<sup>a,b</sup>, Wanxia Gai<sup>a,b</sup>, Benny C. Y. Zee<sup>e</sup>, Brigette B. Y. Ma<sup>Cf</sup>, Edwin P. Hui<sup>c,f</sup>, Anthony T. C. Chan<sup>Cf</sup>, John K. S. Woo<sup>d</sup>, Rossa W. K. Chiu<sup>a,b,c</sup>, and Y. M. Dennis Lo<sup>a,b,c,2</sup>

### Extrapolated performance of the new protocol

 Sensitivity
 : 97.1% (CI: 85.1 - 99.9%)

 Specificity
 : 99.3% (CI: 99.2 - 99.4%)

 False positive rate
 : 140 / (20174-34-1)

 = 0.70% (CI: 0.59 - 0.82%)

 Positive predictive value: 19.5% (CI: 13.9 - 26.2%)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5984543/pdf/pnas. 201804184.pdf





# Liquid biopsy can detect lung cancer 1 - 4 years earlier than CT

Table 2. Clinical and pathological characteristics of CTC-positive COPD patients.

Patients	Sex	-	Smoking status (PY)	Year of COPD diagnosis	GOLD score	Year of CTC Detection (Study entry)	CTCs/CTM		Year of Lung cancer diagnosis	Lung Cancer size (cm)	Histology	Stage	Mutation tumor status	One-year follow-up after surgery
							CTCs	стм						
P1	м	54	60	1998	3	2009	43	1	2012	1.9	Invasive papillary adenocarcinoma	IA	KRAS p.Gly12Cys	No recurrence
P2	F	48	45	1995	2	2009	67	3	2010	1.5	Invasive papillary adenocarcinoma	IA	KRAS p.Gly12Val	No recurrence
P3	м	47	35	1999	2	2008	32	1	2012	1.4	Invasive acinar adenocarcinoma	IA	KRAS p.Gly12Cys	No recurrence
P4	М	52	45	1994	3	2009	19	1	2013	2	Squamous cell carcinoma	IA	<i>STK11</i> (missense mutation)	No recurrence
P5	м	63	55	2001	3	2009	28	1	2013	1.5	Invasive acinar adenocarcinoma	IA	No mutation	No recurrence

Ilie M, Hofman V, Long-Mira E, Selva E, Vignaud J-M, et al. (2014) "Sentinel" Circulating Tumor Cells Allow Early Diagnosis of Lung Cancer in Patients with Chronic Obstructive Pulmonary Disease. PLoS ONE 9(10): e111597. doi:10.1371/journal.pone.0111597





## And the headlines...

Forbes / Pharma & Healthcare / #Medicine

JAN 18, 2018 @ 02:00 PM

### A New \$500 Blood Test Could Detect Cancer Before Symptoms Develop



### Cancer blood test 'enormously exciting'

By James Gallagher Health and science correspondent, BBC News


🕓 19 January 2018 🛛 🛤

🖌 🈏 😒 🗹 < Share

### Science, 19 Jan 2018

### A screening scorecard

A new cancer blood test worked better for some types than others, and caught only 43% of stage 1 cancers. (Error bars represent 95% confidence intervals.)



CancerSEEK is a liquid biopsy test for 8 cancer sites (based on ctDNA from 16 genes, combined with 8 protein biomarkers), developed by a team led by scientists at Johns Hopkins.

1,005 people known to have cancer were tested with 70% detected (but only 46% in Stage 1). 812 healthy people with no cancer history were also tested with 7 (false) positives. Next step will be years of larger prospective clinical trials to demonstrate that the test improves overall cancer survival.



# Studies on genetic testing and its impact on insurance purchasing behaviour

Genetic disease (Gene)	Insurance product	Odds ratio of over- insuring after positive test	Study
Breast cancer (BRCA1/2)	Life insurance	5.1x more likely to increase coverage	Armstrong et al.; 2003 (USA)
Alzheimer's disease (APOE4)	Long-term care insurance	5.7x more likely to change coverage	Taylor et al.; 2005 (USA)
Alzheimer's disease (APOE4)	Long-term care insurance	2.3x more likely to increase coverage	Zick et al.; 2010 (USA)
Huntington's disease (HD)	Long-term care insurance	5x more likely to purchase insurance	Oster et al.; 2010 (USA & Canada)
Colorectal cancer (HNPCC)	Life insurance	1.3x more likely to purchase insurance	Aktan-Collan et al.; 2001 (Finland)

Understanding of consumers acceptance of and concerns about genetic testing is key to investigate the potential impact on insurance purchasing behaviour and level of adverse selection against insurers.






Institute and Faculty of Actuaries

## **Swiss Re's genetic testing consumer survey 2018**

US





UK




Restrictions on access to risk-relevant genetic data will increase insurer's exposure to anti-selection





## **Early Cancer Detection Consortium**

### Early Cancer Detection Consortium





### Consortium Members

The consortium has members from the following University partners:

- University of Cambridge
- Coventry University
- Dublin
- University of Edinburgh
- Lancaster University
- University of Leeds
- University of Leicester
- University of Manchester
- Middlesex University
- University of Nottingham
- University of Oxford
- University of Portsmouth
- Queen Mary University London
- University of Sheffield
- University of St Andrews
- University College London
- University of Warwick

- The biology of cancer is reflected in the blood, suggesting a blood-based screening test for multiple cancer types could be developed. This could revolutionise cancer screening and significantly improve early detection.
- The Early Cancer Detection Consortium brings together expertise from many disciplines to conduct the studies necessary to develop blood-based testing for multiple cancer types.
- The ultimate goal is to produce a strategy for generic cancer screening that can go into clinical practice. This is likely to take the form of a single blood sample on which multiple tests can be done, depending on the results of initial screens.






https://warwick.ac.uk/fac/sci/med/about/centres/uk-ecdc


# **Concerns on insurers using genetic test results for underwriting**

- Four states added questions on genetic testing to the Behavioral Risk Factor Surveillance System health survey.
- The results indicate the majority are concerned about the use of genetic test results by life insurance companies.

How concerned are you that life insurance companies might use genetic test results to determine life insurance coverage and costs: 2010 BRFSS



# Can insurers make use of genetic test results if presented at application stage?



Swiss Re regulatory update 2016

(23 EU countries and 7 other European countries included, alongside 10 Asia and a single African country)





# Regulatory pressure has increased in major life insurance markets

Each market takes a different approach in how it requests/uses genetic testing information to underwrite and assess risk

Insurers generally allowed to:

- Use diagnostic genetic information to <u>confirm</u> disease for underwriting
- Use family history as risk selection tool

### Insurers generally *not* allowed to:


- Ask applicants to undergo genetic testing
- Use existing predictive genetic information for underwriting

Unless: Regulation specifically allows the use of predictive genetic data for high sums insured and/or actuarially justified

### Regulation around how insurers can use genetic data falls into three major categories



# Modelling around the world - Attempt in quantifying the anti-selection impact






## Consumer would share test results in exchange for health management support or reduced premium

### US


### Australia

### UK


Most would share test results in exchange for health management support or reduced premium



Most would share test results in exchange for health management support or reduced premium



Most would share test results in exchange for health management support or reduced premium





Swiss Re's genetic testing consumer survey 2018

## **Summary**



Regulatory restrictions on access and use of genetic information for insurers will increase



Concerns on insurance company using genetic test results for underwriting



Genome sequencing costs will continue to decline



Quick improvement in predictive and pre-symptomatic genetic testing



Anti-selection risk through additional insurance purchase or purchase delay



Acceptance of genetic testing results for underwriting for health promotion or premium discounts



Genetic testing rates in the general population will continue to increase

The future unknown





Institute and Faculty of Actuaries

# Thanks





19 April 2019